A Chinese I/O biotech looking to turn around an old Novartis program gets a new fundraise after launching PhIII study

Close to a year after pulling in its last private fundraise, Chinese immuno-oncology biotech Adlai Nortye is back with another nine-figure round. And it comes as it seeks to continue pushing forward a former experimental Novartis therapy.